Caglayan 1987

Methods	Randomized controlled trial Duration: 17 months, from January 1985 to June 1986
Participants	Number: 120 infants enrolled (no age range specified) Inclusion criteria: post‐BCG vaccine lymphadenitis Exclusion criteria: patients with 'untoward' reactions (not adequately described)
Interventions	Group 1: isoniazid 10 mg/kg/day PO for two months Group 2: isoniazid plus rifampicin 10 mg/kg/day PO for two months Group 3: erythromycin 30 mg/kg/day PO for one month Group 4: no intervention
Outcomes	Clinical failure (abscess formation or lymph node size increased)
Notes	Location: Turkey Setting: not described Source of funding: not described
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described in the study
Allocation concealment (selection bias)	Unclear risk	Not described in the study
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Describe the evaluation of the outcome as 'blind' with no further explanations
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	The authors describe that they were 'blind' to where participants were allocated, although they do not specify how
Incomplete outcome data (attrition bias) All outcomes	Low risk	No patients were lost to follow‐up
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	There was insufficient information to assess whether an important risk of bias exists